AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...

Fasenra is a liquid that is injected under the skin. When you first start using this medicine, you will have an injection every 4 weeks for the first three doses. Then, you will receive a dose ...

Injection site reactions (eg, pain, erythema, pruritus, papule) occurred at a rate of 2.2% in patients treated with FASENRA compared with 1.9% in patients treated with placebo in asthma ...

Fasenra (benralizumab) is a brand-name subcutaneous injection that’s prescribed for severe eosinophilic asthma in certain people. Fasenra hasn’t been reported to interact with alcohol ...

AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...

AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...

Eli Lilly has slashed the prices of starter doses of Zepbound to “significantly” expand the supply of the popular weight loss drug amid high demand in the United States. Single-dose vials ...

5,7 Patients were randomized to receive either a single 30 mg subcutaneous injection of FASENRA, or three separate 100 mg subcutaneous injections of mepolizumab every four weeks. 4,5 In the trial ...

5,7 Patients were randomized to receive either a single 30 mg subcutaneous injection of FASENRA, or three separate 100 mg subcutaneous injections of mepolizumab every four weeks.4,5 In the trial, ...

AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...